Group 1 - The company, Boji Pharmaceutical, is a professional CRO (Contract Research Organization) service provider [2] - It primarily offers outsourced pharmaceutical research and development services to pharmaceutical companies [2] - The company generates revenue by charging technical service fees [2]

Core Insights - The company, Boji Pharmaceutical, has collaborated with over 900 clinical trial service organizations as of the 2024 fiscal year, indicating a strong network in the clinical research sector [2] - Most top-tier hospitals have engaged in partnerships with the company, showcasing its extensive reach and credibility within the healthcare industry [2] Company Summary - Boji Pharmaceutical has established partnerships with more than 900 clinical trial service organizations [2] - The company has collaborated with a majority of top-tier hospitals, enhancing its operational capabilities and market presence [2]

Core Insights - The company, Boji Pharmaceutical, has a significant client base primarily consisting of medium to large domestic pharmaceutical enterprises, having served over 2,000 pharmaceutical companies [2] Company Overview - Boji Pharmaceutical has established itself as a key service provider in the pharmaceutical industry, indicating a strong market presence and extensive experience in the sector [2] - The company's interaction with a diverse range of clients suggests a robust operational capacity and adaptability to various client needs within the pharmaceutical landscape [2] Industry Context - The pharmaceutical industry in China is characterized by a large number of medium to large enterprises, highlighting the competitive nature of the market [2] - The service model employed by Boji Pharmaceutical reflects a trend towards specialized support for pharmaceutical companies, which may enhance operational efficiencies and innovation within the industry [2]

Core Viewpoint - The company, Boji Pharmaceutical, reported that its subsidiary, Jiutai Medical Equipment, is successfully engaged in clinical trials and registration services related to medical devices [2] Company Summary - Boji Pharmaceutical's subsidiary, Jiutai Medical Equipment, is primarily focused on clinical trials and registration application services for medical devices [2] - The company indicated that all business operations are progressing smoothly [2]

Core Viewpoint - The company Boji Pharmaceutical (300404) is actively engaged in providing research and development services for Alzheimer's disease medications [1] Group 1 - The company responded to investor inquiries on July 29, indicating its involvement in Alzheimer's drug development [1]

证券代码：300404 证券简称：博济医药 公告编号：2025-061 博济医药科技股份有限公司 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的两项发明专利证书，具体情况如下： 一、专利基本情况 | 序号 | 发明名称 | 专利权人 | 证书号 | 专利号 | 专利申请日 | | | 授权公告日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种托匹司他的 | 博济医药科 技股份有限 | 第8116481号 | ZL 2023 1 | 2023 | 年 08 | 2025 | 年 07 | | | 制备方法 | 公司 | | 0988381.8 | 月 07 | 日 | 月 | 29 日 | | 2 | 一种鞣酸小檗碱 | 博济医药科 | | ZL 2024 1 | 2024 | 年 11 | 2025 | 年 07 | | | 口服制剂及其制 | 技股份有限 | 第8116823号 | 1565449.2 | 月 05 | 日 | 月 | 29 日 | | | 备方法 | 公司 | | | | | ...

证券代码：300404 证券简称：博济医药 公告编号：2025-060 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次归属限制性股票的激励对象合计 29 名，归属限制性股票数量合计 506,400 股，占目前公司总股本的 0.1315%。 2、本次归属股份的上市流通日：2025 年 7 月 30 日。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第五届董事会第十三次会议和第五届监事会第十二次会议，审议通过了《关于 公司 2023 年限制性股票激励计划首次授予部分第二个解除限售期及预留授予部 分第一个解除限售期解除限售条件成就、首次授予部分第二个归属期归属条件成 就的议案》，董事会认为公司 2023 年限制性股票激励计划（以下简称"本激励 计划"）首次授予部分第二个归属期归属条件已成就。近日，公司办理了第二个 归属期归属股份的登记工作。现将有关情况公告如下： 一、公司 2023 年限制性股票激励计划概述及已履行的相关程序 博济医药科技股份有限公司 关于公司 2023 年限制性股票激励计划 首次授予部 ...

Market Overview - As of July 17, the Shanghai Composite Index closed at 3516.83 points, up 13.05 points, with a gain of 0.37% [1] - The Shenzhen Component Index closed at 10873.62 points, up 152.81 points, with a gain of 1.43% [1] - The ChiNext Index closed at 2269.33 points, up 39.13 points, with a gain of 1.75% [1] Stock Performance - A total of 83 A-shares had a turnover rate exceeding 20% on this day, with Xinning Electric achieving a turnover rate of over 50% [1] - The top stocks by turnover rate included: - Xinning Electric (301388) with a closing price of 38.30 yuan and a turnover rate of 52.50%, up 0.31% [1] - Dayilong (002209) with a turnover rate of 49.98%, closing at 17.09 yuan, down 7.82% [1] - Beifang Changlong (301357) with a turnover rate of 48.34%, closing at 85.47 yuan, up 5.88% [1] - Mankun Technology (301132) with a turnover rate of 45.59%, closing at 39.88 yuan, up 20.01% [1] Notable Stocks - Other notable stocks with high turnover rates included: - Tongguan Copper Foil (301217) with a turnover rate of 40.44%, closing at 20.86 yuan, up 13.37% [1] - Yida Technology (301176) with a turnover rate of 36.95%, closing at 35.16 yuan, up 6.19% [1] - Nanjing Julong (300644) with a turnover rate of 29.86%, closing at 33.59 yuan, up 20.01% [1] Additional Stock Insights - Stocks with significant price movements included: - Huanbo Technology (002229) with a turnover rate of 34.18%, closing at 20.56 yuan, up 10.01% [1] - ST Lifan (300280) with a turnover rate of 24.36%, closing at 3.17 yuan, down 7.85% [2] - Shanghai Steel Union (300226) with a turnover rate of 22.51%, closing at 30.37 yuan, up 2.74% [3]

Core Viewpoint - The brain engineering sector experienced a rise of 1.48% on July 17, with a total capital outflow of 385.08 million [1] Group 1: Stock Performance - A total of 27 stocks in the sector increased in value, while 5 stocks declined [1] - The top-performing stocks included: - Seli Medical: +10.01% - Boji Pharmaceutical: +9.5% - Innovation Medical: +3.23% - Pulite: +3.03% - Beilu Pharmaceutical: +2.6% [1] Group 2: Capital Flow - Major stocks with significant capital inflow included: - Innovation Medical: +16.07 million, accounting for 2.21% - Seli Medical: +199 million, accounting for 15.64% [1] - Stocks with capital outflow included: - Boji Pharmaceutical: -2.46 million, accounting for -2.82% - Beilu Pharmaceutical: -1.41 million, accounting for -3.62% [1] Group 3: Declining Stocks - The stocks that saw the largest declines included: - ST Huatuo: -4.77% - Botuo Bio: -1.59% - Hanwei Technology: -1.49% [1]

Group 1 - The innovative drug sector showed strong performance in the morning session, with Han Commercial Group (600774) hitting the daily limit up [1] - Weikang Pharmaceutical (300878) and Chengdu Xian Dao both surged over 15% [1] - Other companies such as Saily Medical (603716), Nanxin Pharmaceutical, and Boji Pharmaceutical (300404) also experienced gains [1] Group 2 - Dark pool funds are flowing into these stocks, indicating increased investor interest [1]